胸主动脉腔内修复术与最佳药物治疗高危B型壁内血肿的比较:临床研究的系统评价
该系统评价检索多个数据库至2017年9月1日,纳入6项观察性研究、共237例B型壁内血肿患者,其中123例接受胸主动脉腔内修复术联合最佳药物治疗。汇总分析显示,联合治疗组壁内血肿消退率显著高于最佳药物治疗组,进展率和主动脉相关死亡率显著更低;排除Ye K等的研究后差异无统计学意义。
要点
- 胸主动脉腔内修复术联合最佳药物治疗组壁内血肿消退率显著高于最佳药物治疗组(OR 10.0,95%CI 3.43-29.4)。
- 联合治疗组壁内血肿进展率(OR 0.239,95%CI 0.075-0.758)和主动脉相关死亡率(OR 0.248,95%CI 0.085-0.725)显著低于最佳药物治疗组。
- 排除Ye K等的研究后,上述结果差异无统计学意义。
核心结论
- 汇总数据显示,在高危B型壁内血肿患者中,胸主动脉腔内修复术联合最佳药物治疗较最佳药物治疗的壁内血肿消退率显著更高、壁内血肿进展率和主动脉相关死亡率显著更低。
研究设计与样本
- 系统评价,检索PubMed、MEDLINE、EMBASE、CNKI、Google Scholar和Cochrane数据库及部分腔内手术与介入治疗期刊,检索日期为2017年9月1日。
- 纳入报告胸主动脉腔内修复术和最佳药物治疗对B型壁内血肿效果的观察性研究,共纳入6项研究。
- 全部6项研究共237例B型壁内血肿患者,其中123例接受胸主动脉腔内修复术联合最佳药物治疗。
- 由两名独立评价者进行方法学评价和数据提取,采用随机和固定效应模型计算合并效应量估计,并进行敏感性分析。
主要发现
- 胸主动脉腔内修复术联合最佳药物治疗组较最佳药物治疗组的壁内血肿消退率显著更高(OR 10.0,95%CI 3.43-29.4)。
- 胸主动脉腔内修复术联合最佳药物治疗组较最佳药物治疗组的壁内血肿进展率显著更低(OR 0.239,95%CI 0.075-0.758)。
- 胸主动脉腔内修复术联合最佳药物治疗组较最佳药物治疗组的主动脉相关死亡率显著更低(OR 0.248,95%CI 0.085-0.725)。
- 排除Ye K等的研究后,结果显示差异无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 排除Ye K等的研究后,结果显示差异无统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, thoracic endovascular aortic repair (TEVAR) for type B aortic dissection is favorable, but TEVAR for type B intramural hematoma (IMH) remains uncertain. There are numerous clinical (e.g., refractory pain) and radiologic (e.g., IMH thickness) factors that are reported to be associated with IMH progression, challenging the treatment for high-risk type B IMH with high risk factors in clinical practice. OBJECTIVE: The objective of the study was to perform a systematic review of clinical studies to investigate outcomes of TEVAR + best medical treatment (BMT) and BMT in the treatment of high-risk type B IMH. METHODS: The online databases of PubMed, MEDLINE, EMBASE, CNKI, Google Scholar, and Cochrane as well as some journals majoring in endovascular surgery and interventional therapy were searched on September 1, 2017. Observational studies that reported the effect of TEVAR and BMT on type B IMH were included. Two independent reviewers performed methodological assessment and data extraction. Random and fixed effects models were used to calculate pooled effect size estimates. A sensitivity analysis was also carried out. RESULTS: In all 6 included studies, the total number of patients with type B IMH was 237 and 123 patients received TEVAR + BMT. There was a significantly higher IMH regression rate among patients undergoing TEVAR + BMT compared with BMT (odds ratios [OR] 10.0, 95% confidence interval [CI] 3.43-29.4). There were a significantly lower IMH progress rate and aortic-related death rate among patients undergoing TEVAR + BMT compared with BMT (OR 0.239, 95% CI 0.075-0.758; OR 0.248, 95% CI 0.085-0.725). When the study of Ye K et al. was excluded, the results showed no statistically significant differences. CONCLUSIONS: Combined data from the present study demonstrate that TEVAR + BMT results in significantly higher IMH regression rate, lower IMH progression, and lower aortic-related death rate compared with BMT in high-risk type B IMH patients.
引用
- Li L, Jiao Y, Zou J, et al. Thoracic Endovascular Aortic Repair versus Best Medical Treatment for High-Risk Type B Intramural Hematoma: A Systematic Review of Clinical Studies. Ann Vasc Surg. 2018. PMID: 29793011. doi:10.1016/j.avsg.2018.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。